Skip to main content

Table 5 Baseline and treatment-related predictors of the total ASES score at week 104, based on multivariate models

From: Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis

Variables Coefficient (95% CI) p-value Adjusted R2
Clinical/demographic
 Gender (male) 0.32 (0.03, 0.60) 0.030 0.178
 Treatment response −0.46 (−0.65, −0.27) <0.001 0.178
 HAQ −0.73 (−0.97, −0.49) <0.001 0.178
 Pain (VAS) −0.04 (−0.11, 0.03) 0.316 0.177
 Fatigue (VAS) −0.06 (−0.12, 0.01) 0.083 0.182
 PGA −0.01 (−0.08, 0.07) 0.733 0.182
 PhGA −0.01 (−0.11, 0.09) 0.607 0.175
SF-36
 MCS 0.31 (0.19, 0.43) <0.001 0.230
 Vitality 0.16 (0.08, 0.24) <0.001 0.210
 Social function 0.08 (0.02, 0.15) 0.008 0.191
 Mental health 0.21 (0.13, 0.28) <0.001 0.235
 Role emotional 0.07 (0.04, 0.10) <0.001 0.218
IPQ-R
 Illness coherence 0.07 (0.04, 0.10) <0.001 0.215
 Treatment control 0.09 (0.03, 0.14) 0.002 0.197
 Personal control 0.05 (0.01, 0.09) 0.008 0.191
 Emotional representations −0.07 (−0.10, −0.05) <0.001 0.261
 Consequences −0.07 (−0.10, −0.03) <0.001 0.208
UCL
 Passive reacting −0.08 (−0.12, −0.04) <0.001 0.186
 Active tackling 0.03 (−0.01, 0.07) 0.090 0.182
RAQoL −0.04 (−0.07, −0.02) 0.001 0.199
  1. Results were obtained from multivariate linear regression models predicting the total ASES score at week 104 by predictors that were significant in univariate analyses and adjusting for age, gender, treatment type and response, auto-antibody status, cumulative CRP, cumulative SJC28 and baseline HAQ and DAS28-CRP or its components. Treatment response was treated as an ordinal variable with lower values representing earlier and more persistent response
  2. Bonferroni correction for multiple comparisons was applied, setting the significance level at p < 0.003
  3. ASES Arthritis Self-Efficacy Scale, SF-36 Short-Form 36, MCS mental component score, IPQ-R Revised Illness Perception Questionnaire, UCL Utrecht Coping List